Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.

(Reuters) -British homebuilder Barratt Redrow said it would buy back shares worth 100 million pounds ($124 million) per year ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

Tuesday unveiled its strategic outlook for the year and said that 2025 will be decisive for the company, with several major initiatives to accelerate the clinical development of BIO101 ...

The regional executive of the Pittsburgh branch of the Federal Reserve Bank of Cleveland spoke at the Economic Update ...

As the Greenback gives away part of the CPI-led jump to weekly tops, GBP/USD manages to gather some traction and return to ...

There's a reason for that. In a recent support article, Microsoft acknowledged that Outlook may crash when you start a new email or when you reply to or forward an existing email. To see which ...

With the first practice session of the new IndyCar Season due to begin at St. Petersburg on Friday, February 28, it’s time to ...

Nearly three-fourths of responding real estate developers plan to start new multifamily projects in California within the ...

Outlook Therapeutics has also acknowledged the ... The company is also preparing for a 2025 launch in Europe, where the treatment has already been approved. These are the latest developments ...

The highly anticipated GTA VI is set to launch in the fall of 2025. "This calendar year is shaping up to be one of the strongest ever for Take-Two," said CEO Strauss Zelnick. He expressed ...

Sukhtian expressed gratitude towards Thurman for his leadership, highlighting the pivotal role Outlook Therapeutics is set to play in improving patient health with the upcoming product launch.